Product Description
Mechanisms of Action: MMP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer
Phase 2: Bone Cancer|Sarcoma, Kaposi|Prostate Cancer|Adenocarcinoma|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00040755 |
NCI-2013-00041 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma|Bone Cancer |
2006-07-01 |
2019-03-21 |
Treatments |
|
NCT00039104 |
NCI-2012-02799 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2005-01-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT00024024 |
NCI-2012-02410 | P2 |
Completed |
Sarcoma, Kaposi |
2003-08-01 |
2019-03-21 |
Treatments |
|
NCT00036621 |
CA161-006 | P2 |
Terminated |
Breast Cancer |
2002-09-01 |
2019-03-21 |
Treatments |
|
NCT00006229 |
BR18 | P3 |
Completed |
Non-Small-Cell Lung Cancer |
2003-12-10 |
2020-03-26 |
Primary Completion Date|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|